Minireviews
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Clin Urol. Mar 24, 2014; 3(1): 31-37
Published online Mar 24, 2014. doi: 10.5410/wjcu.v3.i1.31
Systematic review of the non surgical management of Peyronie's disease
Paolo Verze, Davide Arcaniolo, Tommaso Cai, Marco Franco, Roberto La Rocca, Mario Acquaviva, Lorenzo Spirito, Aleksandre Bochorishvili, Vincenzo Mirone
Paolo Verze, Davide Arcaniolo, Tommaso Cai, Marco Franco, Roberto La Rocca, Mario Acquaviva, Lorenzo Spirito, Vincenzo Mirone, Department of Neuroscience, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples Federico II, 80131 Naples, Italy
Aleksandre Bochorishvili, National Centre of Urology, 00144 Tbilisi Georgia, Italy
Author contributions: Verze P, Arcaniolo D and Mirone V contributed to drafting manuscript; Verze P and Mirone V contributed to final review of the content; Cai T, Franco M, La Rocca R, Acquaviva M, Spirito L and Bochorishvili A contributed to selecting studies; Acquaviva M and Spirito L contributed to reference listing.
Correspondence to: Paolo Verze, MD, PhD, Department of Neuroscience, Reproductive Sciences and Odontostomatology, Urology Unit, University of Naples Federico II, Via S. Pansini, 80131 Naples, Italy. pverze@gmail.com
Telephone: +39-081-7462611 Fax: +39-081-7462611
Received: December 24, 2013
Revised: February 3, 2014
Accepted: February 16, 2014
Published online: March 24, 2014
Core Tip

Core tip: Ince the first medical publication on Peyronie’s Disease, physicians have proposed several medical alternatives for treatment of this disease. As of today nonsurgical options are currently available. A consistent number of non-surgical treatment options that offer some benefit with respect to disease stabilization, alleviation, as well as reduction of deformity and improved sexual function are available including oral treatment with potassium para-aminobenzoate, intralesional treatment with interferon, iontophoresis with verapamil 5 mg and dexamethasone 8 mg and extracorporeal shock-wave treatment.